Iovance climbs on positive mid-stage data for skin cancer treatment

Iovance Biotherapeutics

24/05/2024 10:52

** Shares of cell therapy developer Iovance Biotherapeutics
 IOVA.O  rise 6.4% to $10.86 premarket
    ** IOVA says its cell therapy lifileucel in combination with
Keytruda showed 30% complete response rate in patients with a
type of skin cancer called advanced melanoma
    ** A complete response is disappearance of all signs of
cancer in response to treatment
    ** Up to last close, stock up 26.2% YTD
    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))